Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study
- DOI
- 10.1016/j.esmoop.2024.104083
- Published
- 2024-12
- Container
- ESMO Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2024.104083,
title = {Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study},
author = {H. Jourdain and A. Di Meglio and I. Mansouri and D. Desplas and M. Zureik and N. Haddy},
year = {2024},
journal = {ESMO Open},
doi = {10.1016/j.esmoop.2024.104083},
url = {https://doi.org/10.1016/j.esmoop.2024.104083}
}RIS
TY - JOUR TI - Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study AU - H. Jourdain AU - A. Di Meglio AU - I. Mansouri AU - D. Desplas AU - M. Zureik AU - N. Haddy PY - 2024 JO - ESMO Open DO - 10.1016/j.esmoop.2024.104083 UR - https://doi.org/10.1016/j.esmoop.2024.104083 ER -
APA
Jourdain, H., Meglio, A. D., Mansouri, I., Desplas, D., Zureik, M., & Haddy, N. (2024). Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study. ESMO Open. https://doi.org/10.1016/j.esmoop.2024.104083
Source records
- crossref · retrieved 2026-09-26T11:01:18.555Z